Table 2.

Risk of AML/MDS Transformation in Patients With MPNs in Relation to Cumulative Dose

Cumulative Dose					All Patient Cases and Controls
	Patient Cases		Controls		Risk of AML/MDS		Risk of AML/MDS		Risk of AML Only		Patient Cases and Controls With PV/ET Risk of AML/MDS
	No.	%	No.	%	Crude OR	95% CI	Adjusted OR*	95% CI	Adjusted OR*	95% CI	Adjusted OR*	95% CI
Total No. of patients	162	100	242	100
HU, g
0	111	69	179	74	1.0	Ref	1.0	Ref	1.0	Ref	1.0	Ref
1-499	24	15	29	12	1.3	0.7 to 2.6	1.5	0.6 to 2.4	1.3	0.6 to 2.5	1.0	0.4 to 2.5
500-999	14	9	15	6	1.3	0.6 to 3.1	1.4	0.6 to 3.4	1.5	0.6 to 3.6	0.9	0.3 to 2.6
≥ 1,000	13	8	19	8	1.0	0.4 to 2.3	1.3	0.5 to 3.3	1.1	0.4 to 3.0	1.2	0.5 to 3.2
Trend test P					.510		.320		.370		.600
P32, MBq
0	92	57	161	67	1.0	Ref	1.0	Ref	1.0	Ref	1.0	Ref
1-499	14	9	21	9	1.3	0.6 to 2.8	1.5	0.6 to 3.3	1.3	0.6 to 3.1	1.4	0.6 to 3.2
500-999	16	10	32	13	0.9	0.5 to 1.8	1.1	0.5 to 2.2	0.9	0.4 to 1.9	1.2	0.6 to 2.5
≥ 1,000	40	25	28	12	4.0	1.9 to 8.3	4.6	2.1 to 9.8	4.8	2.0 to 9.9	4.4	2.0 to 9.6
Trend test P					.006		.002		.006		.003
Alkylating agents, g
0	124	77	196	81	1.0	Ref	1.0	Ref	1.0	Ref	1.0	Ref
0.1-0.49	15	9	26	11	1.0	0.5 to 2.0	1.1	0.5 to 2.3	1.0	0.5 to 2.1	1.2	0.5 to 2.7
0.50-0.99	11	7	12	5	1.7	0.6 to 4.4	1.7	0.6 to 5.0	1.4	0.5 to 4.4	2.1	0.7 to 6.4
≥ 1.00	12	7	8	3	3.0	1.0 to 8.8	3.4	1.1 to 10.6	3.2	1.0 to 10.0	3.6	1.1 to 11.2
Trend test P					.030		.015		.032		.007

Abbreviations: AML, acute myeloid leukemia; ET, essential thrombocythemia; HU, hydroxyurea; MDS, myelodysplastic syndrome; MPN, chronic myeloproliferative neoplasm; OR, odds ratio; P³², radioactive phosphorus; PV, polycythemia vera; Ref, reference.

^*Mutually adjusted for other treatments.